Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced recently the appointment of Mark Lo Chun Bun as CFO of the Group.
Lo has more than 20 years of executive financial management experience in the pharmaceutical industry, in particular, in manufacturing, logistics and distribution, the firm said.
He is also experienced in advising and nurturing innovative startups in areas of biotechnology, diagnostics and medical device, the firm added.
Lo in his new role is charged with the responsibilities for financial planning, budgeting, control, analysis, reporting and overall management of finance team of the group.
He was previously an executive director of Hong Kong-listed Jacobson Pharma Corporation, responsible for the overall financial management functions.
Immuno Cure said it has two PD-1-Enhanced DNA vaccines currently advancing to phase 2 clinical trial for prevention of COVID-19 and phase 1 clinical trial for therapeutic functional cure of HIV/AIDS.
